To help prevent a growing number of cases of menopausis, a form of dementia that affects around one in five adults, the European Union is to introduce a new herb known as herbal medicine.
The new regulation will take effect in July.
It will apply to products and services that contain herbal medicines, including supplements, extracts and creams.
The herb, named Kratom, is a tropical herb that is used in many parts of Asia, particularly in Malaysia, Thailand, Vietnam and Indonesia.
Kratom is a mixture of three compounds, called mitragynine, mitragol and 5-hydroxymitragynidine, the first two of which are known as alkaloids.
It is a mild stimulant and a relaxing agent, helping to reduce pain and fatigue and easing mood swings.
Karmacists have already been able to prescribe Kratom as an alternative to traditional medicines.
However, the herbal medicines market is a big one, with the European Commission estimating that it represents $15 billion in sales annually.
There are more than 40,000 herbal medicines in Europe and they include medicines to treat pain, cough, fever and colds, to treat headaches, asthma and muscle aches, to relieve muscle spasms, and to treat osteoporosis.
Kompromat is a painkiller that has been prescribed to more than 7 million people worldwide since 2002.
Its popularity is largely due to its ability to help ease pain and other symptoms of osteoporsosis.
According to the European Medicines Agency (EMA), the drug is considered safe and well tolerated by people over 55 years of age.
However the DEA said it has not shown any clear evidence that it is effective in reducing the number of menopausal symptoms.
The EMA said that the drug has been shown to be safe for people over 65 years of experience.
Koprofen, a prescription pain reliever that has also been prescribed by doctors, is also under consideration, but its approval is likely to be delayed.
The FDA is considering whether to approve a prescription drug called Opana.
It has already approved two other prescription drugs in the United States, including one to treat chronic pain.
In March, the US Food and Drug Administration said that it had approved Opana, but the company is yet to send the drug to patients for approval.
The European Medicine Agency has been working closely with the Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and other international agencies to help identify the best ingredients and brands of the new herbal medicines.
The agency has also begun testing the Kratom to see if it is safe.
Ketamine is a type of synthetic opioid.
It was first identified in Europe in the 1930s, but was first approved in the US in 1972.
Kemetamine has also attracted attention in other countries, particularly Thailand, where it is being used to treat opioid addiction.
It can help reduce the withdrawal symptoms of opioid withdrawal and is a popular treatment for those suffering from chronic pain and depression.
A number of countries are also using it to treat menopales.
In April, the Dutch Medicines Authority said that they were testing a number of herbal medicines for their ability to treat depression.
In December, a Thai court ruled that the government must stop selling the herb after a woman died from menopaui due to a shortage of the drug.
The UK also has a national ban on the sale of Kratom.